Threshold Pharmaceuticals (THLD) receives orphan drug designation in the EU for its TH-302...

|About: Threshold Pharmaceuticals... (THLD)|By:, SA News Editor

Threshold Pharmaceuticals (THLD) receives orphan drug designation in the EU for its TH-302 treatment for soft tissue sarcoma after early studies showed positive results with patients. The company is currently in critical phase 3 testing on the drug. Shares +4.5% premarket.